Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis.

Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA, Chapman HA.

J Clin Invest. 2009 Jan;119(1):213-24. doi: 10.1172/JCI36940. Epub 2008 Dec 22.

2.

TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease.

Willis BC, Borok Z.

Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L525-34. Epub 2007 Jul 13. Review.

3.

Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages.

Uhal BD, Kim JK, Li X, Molina-Molina M.

Curr Pharm Des. 2007;13(12):1247-56. Review.

PMID:
17504233
4.

Sphingolipids in pulmonary fibrosis.

Huang LS, Natarajan V.

Adv Biol Regul. 2015 Jan;57:55-63. doi: 10.1016/j.jbior.2014.09.008. Epub 2014 Oct 13. Review.

5.

Epithelial origin of myofibroblasts during fibrosis in the lung.

Willis BC, duBois RM, Borok Z.

Proc Am Thorac Soc. 2006 Jun;3(4):377-82. Review.

6.

New insights into epithelial-mesenchymal transition in kidney fibrosis.

Liu Y.

J Am Soc Nephrol. 2010 Feb;21(2):212-22. doi: 10.1681/ASN.2008121226. Epub 2009 Dec 17. Review.

7.

Breakdown of Epithelial Barrier Integrity and Overdrive Activation of Alveolar Epithelial Cells in the Pathogenesis of Acute Respiratory Distress Syndrome and Lung Fibrosis.

Yanagi S, Tsubouchi H, Miura A, Matsumoto N, Nakazato M.

Biomed Res Int. 2015;2015:573210. doi: 10.1155/2015/573210. Epub 2015 Oct 7. Review.

8.

Distinct Roles of Wnt/β-Catenin Signaling in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.

Shi J, Li F, Luo M, Wei J, Liu X.

Mediators Inflamm. 2017;2017:3520581. doi: 10.1155/2017/3520581. Epub 2017 May 9. Review.

9.

Hepatocyte growth factor in lung repair and pulmonary fibrosis.

Panganiban RA, Day RM.

Acta Pharmacol Sin. 2011 Jan;32(1):12-20. doi: 10.1038/aps.2010.90. Epub 2010 Dec 6. Review.

10.

Evolving concepts of apoptosis in idiopathic pulmonary fibrosis.

Thannickal VJ, Horowitz JC.

Proc Am Thorac Soc. 2006 Jun;3(4):350-6. Review.

11.

Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Shu DY, Lovicu FJ.

Prog Retin Eye Res. 2017 Sep;60:44-65. doi: 10.1016/j.preteyeres.2017.08.001. Epub 2017 Aug 12. Review.

PMID:
28807717
12.

Mechanisms of lung fibrosis induced by carbon nanotubes: towards an Adverse Outcome Pathway (AOP).

Vietti G, Lison D, van den Brule S.

Part Fibre Toxicol. 2016 Feb 29;13:11. doi: 10.1186/s12989-016-0123-y. Review.

13.

Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.

Sakuma Y.

Pathol Int. 2017 Aug;67(8):379-388. doi: 10.1111/pin.12553. Epub 2017 Jul 5. Review.

PMID:
28678431
14.

Mechanisms of alveolar epithelial injury, repair, and fibrosis.

Chambers RC, Mercer PF.

Ann Am Thorac Soc. 2015 Mar;12 Suppl 1:S16-20. doi: 10.1513/AnnalsATS.201410-448MG. Review.

15.

Paracrine functions of fibrocytes to promote lung fibrosis.

Kleaveland KR, Moore BB, Kim KK.

Expert Rev Respir Med. 2014 Apr;8(2):163-72. doi: 10.1586/17476348.2014.862154. Epub 2014 Jan 22. Review.

16.

Epithelial-mesenchymal transition: An emerging target in tissue fibrosis.

Li M, Luan F, Zhao Y, Hao H, Zhou Y, Han W, Fu X.

Exp Biol Med (Maywood). 2016 Jan;241(1):1-13. doi: 10.1177/1535370215597194. Epub 2015 Sep 11. Review.

17.

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.

Camelo A, Dunmore R, Sleeman MA, Clarke DL.

Front Pharmacol. 2014 Jan 10;4:173. doi: 10.3389/fphar.2013.00173. eCollection 2014 Jan 10. Review.

18.

Epithelial-mesenchymal transition in tissue repair and fibrosis.

Stone RC, Pastar I, Ojeh N, Chen V, Liu S, Garzon KI, Tomic-Canic M.

Cell Tissue Res. 2016 Sep;365(3):495-506. doi: 10.1007/s00441-016-2464-0. Epub 2016 Jul 27. Review.

19.

MicroRNAs as potential targets for progressive pulmonary fibrosis.

Rajasekaran S, Rajaguru P, Sudhakar Gandhi PS.

Front Pharmacol. 2015 Nov 5;6:254. doi: 10.3389/fphar.2015.00254. eCollection 2015. Review.

20.

Myofibroblast differentiation and survival in fibrotic disease.

Kis K, Liu X, Hagood JS.

Expert Rev Mol Med. 2011 Aug 23;13:e27. doi: 10.1017/S1462399411001967. Review.

Supplemental Content

Support Center